🔗 Share this article World Health Organization Raises Warning Over Critical Lack of Weight-Loss Injections Under a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it releases its inaugural recommendations on the therapies. Considering over a billion people worldwide now living with obesity, it is urging broader and more equitable access to this class of drugs. According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "The latest guidance affirms that obesity is a chronic disease that can be treated with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are key barriers to universal access to the jabs that can assist patients in reducing substantial body mass, explains the agency. Skinny Jab Shortage Even under the present most optimistic case, the production of these medications might only reach around 100 million people – less than 10% of eligible patients, per the health organization. The advice encourages governments and firms to expand access, via measures like voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026. How Obesity Jabs Function These medications replicate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals eat less. People usually see weight reduction after several weeks of beginning the weekly injections. Evidence suggests users may put most of the weight back on after a year of stopping the drug, when their typical food cravings return. To be above a healthy weight raises your chance for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain malignancies. Excess weight concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
Under a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it releases its inaugural recommendations on the therapies. Considering over a billion people worldwide now living with obesity, it is urging broader and more equitable access to this class of drugs. According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "The latest guidance affirms that obesity is a chronic disease that can be treated with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are key barriers to universal access to the jabs that can assist patients in reducing substantial body mass, explains the agency. Skinny Jab Shortage Even under the present most optimistic case, the production of these medications might only reach around 100 million people – less than 10% of eligible patients, per the health organization. The advice encourages governments and firms to expand access, via measures like voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026. How Obesity Jabs Function These medications replicate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals eat less. People usually see weight reduction after several weeks of beginning the weekly injections. Evidence suggests users may put most of the weight back on after a year of stopping the drug, when their typical food cravings return. To be above a healthy weight raises your chance for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain malignancies. Excess weight concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.